Progyny (NASDAQ:PGNY) Reaches New 1-Year Low – Should You Sell?

Shares of Progyny, Inc. (NASDAQ:PGNY) reached a new 52-week low on Tuesday . The stock traded as low as $16.60 and last traded at $16.65, with a volume of 143723 shares traded. The stock had previously closed at $16.97.

Analyst Upgrades and Downgrades

PGNY has been the topic of a number of recent analyst reports. Citizens Jmp raised Progyny from a “market perform” rating to an “outperform” rating and set a $30.00 price objective on the stock in a research note on Tuesday, January 20th. Zacks Research cut Progyny from a “strong-buy” rating to a “hold” rating in a research note on Friday, January 30th. Wall Street Zen upgraded Progyny from a “hold” rating to a “buy” rating in a report on Saturday, January 3rd. JPMorgan Chase & Co. set a $35.00 price target on Progyny in a research note on Wednesday, January 21st. Finally, BTIG Research cut their price target on Progyny from $35.00 to $30.00 and set a “buy” rating on the stock in a report on Thursday, March 5th. Nine analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $27.91.

Progyny Stock Down 0.7%

The firm’s 50 day simple moving average is $20.11 and its two-hundred day simple moving average is $22.24. The stock has a market capitalization of $1.38 billion, a P/E ratio of 25.94, a P/E/G ratio of 0.98 and a beta of 1.01.

Progyny (NASDAQ:PGNY) last released its quarterly earnings data on Thursday, February 26th. The company reported $0.48 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.38 by $0.10. Progyny had a net margin of 4.54% and a return on equity of 11.37%. The company had revenue of $318.40 million for the quarter, compared to analysts’ expectations of $314.26 million. During the same quarter in the prior year, the firm earned $0.42 EPS. The business’s revenue was up 6.7% on a year-over-year basis. Progyny has set its FY 2026 guidance at 1.830-1.950 EPS and its Q1 2026 guidance at 0.420-0.450 EPS. As a group, equities research analysts expect that Progyny, Inc. will post 0.6 earnings per share for the current year.

Insider Transactions at Progyny

In other Progyny news, EVP Allison Swartz sold 4,657 shares of the firm’s stock in a transaction that occurred on Tuesday, March 3rd. The stock was sold at an average price of $17.40, for a total value of $81,031.80. Following the completion of the sale, the executive vice president owned 89,879 shares of the company’s stock, valued at approximately $1,563,894.60. This trade represents a 4.93% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders sold a total of 7,455 shares of company stock valued at $129,515 in the last 90 days. 9.40% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Progyny

A number of large investors have recently modified their holdings of PGNY. Wellington Management Group LLP increased its stake in Progyny by 260.9% during the 4th quarter. Wellington Management Group LLP now owns 2,243,268 shares of the company’s stock valued at $57,607,000 after purchasing an additional 1,621,688 shares in the last quarter. Loomis Sayles & Co. L P bought a new position in shares of Progyny in the fourth quarter valued at $19,917,000. Barclays PLC lifted its stake in shares of Progyny by 79.2% in the third quarter. Barclays PLC now owns 1,575,470 shares of the company’s stock valued at $33,904,000 after buying an additional 696,447 shares in the last quarter. Ameriprise Financial Inc. grew its holdings in shares of Progyny by 37.6% during the second quarter. Ameriprise Financial Inc. now owns 1,996,957 shares of the company’s stock valued at $43,933,000 after buying an additional 545,431 shares during the last quarter. Finally, Nomura Holdings Inc. acquired a new position in shares of Progyny during the second quarter valued at about $9,368,000. 94.93% of the stock is currently owned by institutional investors.

Progyny Company Profile

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.